<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602598</url>
  </required_header>
  <id_info>
    <org_study_id>58497</org_study_id>
    <nct_id>NCT04602598</nct_id>
  </id_info>
  <brief_title>Zanubrutinib in Patients With IgG4-Related Disease</brief_title>
  <official_title>A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew C. Baker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in&#xD;
      treating patients with IgG4-related disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-site, open-label study in symptomatic patients with IgG4-related&#xD;
      disease affecting the submandibular and/or lacrimal glands. All patients will receive&#xD;
      zanubrutinib orally at a dose of 80mg BID for 24 weeks.&#xD;
&#xD;
      The primary objective of this study is to demonstrate that zanubrutinib treatment reduces&#xD;
      reduces the volume of the submandibular and/or lacrimal glands on PET/MRI at week 24 compared&#xD;
      to baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label study in symptomatic subjects with histopathologically confirmed IgG4-related disease affecting the submandibular and/or lacrimal glands. Ten subjects will be included in the study. All eligible subjects will receive zanubrutinib 80mg BID over a period of 24 weeks and will be followed up for an additional 8 weeks after the last dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of the submandibular glands on PET-MRI</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To demonstrate that zanubrutinib treatment reduces the volume of the submandibular glands on PET-MRI at Week 24 compared to Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of the lacrimal glands on PET-MRI</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To demonstrate that zanubrutinib treatment reduces the volume of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FDG avidity (SUVmax) of the submandibular glands on PET-MRI</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Effect of zanubrutinib on change in FDG avidity (SUVmax) of the submandibular glands on PET-MRI at Week 24 compared to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG avidity (SUVmax) of the lacrimal glands on PET-MRI</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Effect of zanubrutinib on change in FDG avidity (SUVmax) of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>IgG4 Related Disease</condition>
  <arm_group>
    <arm_group_label>Zanubrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanubrutinib orally at a dose of 80mg BID for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib 80 MG</intervention_name>
    <description>Zanubrutinib 80 MG for 24 weeks</description>
    <arm_group_label>Zanubrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged 18 to 85, inclusive, at the time of initial screening&#xD;
&#xD;
          -  Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the&#xD;
             lacrimal gland confirmed by international consensus pathology criteria&#xD;
&#xD;
               -  Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per&#xD;
                  high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%&#xD;
&#xD;
          -  All women must test negative for pregnancy and agree to use a reliable method of birth&#xD;
             control&#xD;
&#xD;
          -  No current treatment with immunosuppressive medications other than prednisone 40mg&#xD;
             daily (or other glucocorticoid equivalent) with stable dosing for 28 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable prescribed dose of glucocorticoids within 28 days prior to baseline&#xD;
&#xD;
          -  Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,&#xD;
             methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline&#xD;
&#xD;
          -  Any treatment with a cytotoxic or immunosuppressive drug including but not limited to&#xD;
             cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or&#xD;
             tacrolimus within 28 days prior to baseline&#xD;
&#xD;
          -  Any treatment with a BTK inhibitor within 6 months before baseline&#xD;
&#xD;
          -  Any treatment with a JAK inhibitor within 28 days prior to baseline&#xD;
&#xD;
          -  Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days&#xD;
             prior to baseline&#xD;
&#xD;
          -  Use of a B cell depleting therapy (such as rituximab) within 12 months prior to&#xD;
             baseline&#xD;
&#xD;
          -  A history of, or current, inflammatory or autoimmune disease (that could affect the&#xD;
             interpretation of safety or efficacy outcomes) other than IgG4-related disease&#xD;
&#xD;
          -  Evidence of active tuberculosis, HIV, or hepatitis B or C infection&#xD;
&#xD;
          -  History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma&#xD;
             in situ (cured &gt;1 year), prostate cancer (cured &gt;5 years), or colon cancer (cured &gt;5&#xD;
             years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew C Baker, MD</last_name>
    <phone>650-497-0774</phone>
    <email>mbaker13@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angie R Aberia, BA</last_name>
    <phone>650-723-8516</phone>
    <email>aaberia@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Matthew C. Baker</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G4-Related Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

